Related references
Note: Only part of the references are listed.A group of infection-enhancing and focus size-reducing monoclonal antibodies recognized an 'a and c' strands epitope in the pr domain of Dengue Virus prM
Poonsook Keelapang et al.
VIRUS RESEARCH (2023)
Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody
Poonsook Keelapang et al.
MICROBIOLOGY SPECTRUM (2023)
Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003)
Luis Rivera et al.
CLINICAL INFECTIOUS DISEASES (2022)
A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
Usha K. Nivarthi et al.
NATURE COMMUNICATIONS (2021)
Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)
Laura J. White et al.
PLOS NEGLECTED TROPICAL DISEASES (2021)
Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection
Henrik Salje et al.
NATURE MEDICINE (2021)
Implementation strategies for the first licensed dengue vaccine: A meeting report
Noah Fongwen et al.
VACCINE (2021)
Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data
Daniel J. Laydon et al.
ELIFE (2021)
A simple approach to identify functional antibody variable genes in murine hybridoma cells that coexpress aberrant kappa light transcripts by restriction enzyme digestion
Romchat Kraivong et al.
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2021)
Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection
Sandra Henein et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Mapping global variation in dengue transmission intensity
Lorenzo Cattarino et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial
Shibadas Biswal et al.
LANCET (2020)
High flavivirus structural plasticity demonstrated by a non-spherical morphological variant
Seamus R. Morrone et al.
NATURE COMMUNICATIONS (2020)
Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine
Annelies Wilder-Smith et al.
LANCET INFECTIOUS DISEASES (2019)
The Dengue ED3 Dot Assay, a Novel Serological Test for the Detection of Denguevirus Type-Specific Antibodies and Its Application in a Retrospective Seroprevalence Study
Heidi Auerswald et al.
VIRUSES-BASEL (2019)
Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies
Rajendra Raut et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
S. Sridhar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope
Stefan W. Metz et al.
VIROLOGY JOURNAL (2018)
Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine
Yang Yang et al.
CLINICAL INFECTIOUS DISEASES (2018)
Strategies to improve the immunogenicity of prM plus E dengue virus type-2 DNA vaccine
Chutitorn Ketloy et al.
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2017)
Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals
Sandra Henein et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Human CD4+ T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity
Michael A. Angelo et al.
JOURNAL OF VIROLOGY (2017)
Disease and economic burdens of dengue
Marcia C Castro et al.
LANCET INFECTIOUS DISEASES (2017)
Antibody-dependent enhancement of severe dengue disease in humans
Leah C. Katzelnick et al.
SCIENCE (2017)
Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America
Gustavo Olivera-Botello et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort
Leah C. Katzelnick et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model
Beth D. Kirkpatrick et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Anti-dengue virus envelope protein domain III IgG ELISA among infants with primary dengue virus infections
Daniel H. Libraty et al.
ACTA TROPICA (2015)
Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults
Beth D. Kirkpatrick et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus (vol 16, pg 171, 2015)
Wanwisa Dejnirattisai et al.
NATURE IMMUNOLOGY (2015)
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
S. R. Hadinegoro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
Luis Villar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells
Amporn Suphatrakul et al.
VACCINE (2015)
A New Quaternary Structure Epitope on Dengue Virus Serotype 2 Is the Target of Durable Type-Specific Neutralizing Antibodies
E. N. Gallichotte et al.
MBIO (2015)
Functional analysis of dengue virus (DENV) type 2 envelope protein domain 3 type-specific and DENV complex-reactive critical epitope residues
Trevor J. Pitcher et al.
JOURNAL OF GENERAL VIROLOGY (2015)
Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope
Luke N. Robinson et al.
CELL (2015)
A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface
Guntur Fibriansah et al.
EMBO MOLECULAR MEDICINE (2014)
An optimized expression vector for improving the yield of dengue virus-like particles from transfected insect cells
Nicha Charoensri et al.
JOURNAL OF VIROLOGICAL METHODS (2014)
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
Maria Rosario Capeding et al.
LANCET (2014)
Induction of Neutralizing Antibody Response against Four Dengue Viruses in Mice by Intramuscular Electroporation of Tetravalent DNA Vaccines
Eakachai Prompetchara et al.
PLOS ONE (2014)
Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand
Chukiat Sirivichayakul et al.
VIROLOGY JOURNAL (2014)
A Simplified Positive-Sense-RNA Virus Construction Approach That Enhances Analysis Throughput
Bunpote Siridechadilok et al.
JOURNAL OF VIROLOGY (2013)
Generation and preclinical evaluation of a DENV-1/2 prM + E chimeric live attenuated vaccine candidate with enhanced prM cleavage
Poonsook Keelapang et al.
VACCINE (2013)
The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1
Yang Zhou et al.
VIROLOGY (2013)
Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus
Joseph J. B. Cockburn et al.
EMBO JOURNAL (2012)
Structural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-Reactivity
Claire M. Midgey et al.
JOURNAL OF IMMUNOLOGY (2012)
Efficacy of a Tetravalent Chimeric Dengue Vaccine (DENVax) in Cynomolgus Macaques
Jorge E. Osorio et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2011)
Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines
Rosario Z. Capeding et al.
VACCINE (2011)
Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice
Shuo Zhang et al.
VIROLOGY JOURNAL (2011)
Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use
Iris Valdes et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2010)
Influence of pr-M Cleavage on the Heterogeneity of Extracellular Dengue Virus Particles
Jiraphan Junjhon et al.
JOURNAL OF VIROLOGY (2010)
Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization
Vainav Patel et al.
VACCINE (2010)
Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy
Monika Simmons et al.
VIROLOGY (2010)
Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens
Wayne D. Crill et al.
PLOS ONE (2009)
Efficient Assembly and Secretion of Recombinant Subviral Particles of the Four Dengue Serotypes Using Native prM and E Proteins
Pei-Gang Wang et al.
PLOS ONE (2009)
Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody
W. M. P. B. Wahala et al.
VIROLOGY (2009)
Differential Modulation of prM Cleavage, Extracellular Particle Distribution, and Virus Infectivity by Conserved Residues at Nonfurin Consensus Positions of the Dengue Virus pr-M Junction
Jiraphan Junjhon et al.
JOURNAL OF VIROLOGY (2008)
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes
Soila Sukupolvi-Petty et al.
JOURNAL OF VIROLOGY (2007)
Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys
JE Blaney et al.
JOURNAL OF VIROLOGY (2005)
Alterations of pr-M cleavage and virus export in pr-M junction chimeric dengue viruses
P Keelapang et al.
JOURNAL OF VIROLOGY (2004)
Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: Genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates
F Guirakhoo et al.
VIROLOGY (2002)
Development of a fluorogenic RT-PCR system for quantitative identification of dengue virus serotypes 1-4 using conserved and serotype-specific 3′ noncoding sequences
HSH Houng et al.
JOURNAL OF VIROLOGICAL METHODS (2001)
Live attenuated tetravalent dengue vaccine
N Bhamarapravati et al.
VACCINE (2000)
Share Paper
